ES2187334B1 - Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. - Google Patents

Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Info

Publication number
ES2187334B1
ES2187334B1 ES200100105A ES200100105A ES2187334B1 ES 2187334 B1 ES2187334 B1 ES 2187334B1 ES 200100105 A ES200100105 A ES 200100105A ES 200100105 A ES200100105 A ES 200100105A ES 2187334 B1 ES2187334 B1 ES 2187334B1
Authority
ES
Spain
Prior art keywords
sub
group
hydrazide
pharmaceutical compositions
new derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES200100105A
Other languages
English (en)
Other versions
ES2187334A1 (es
Inventor
Antonio Monge Vega
Ignacio Aldana Moraza
Daniel-Henri Caignard
Nigel Levens
Michel Feletou
Odile Della Zuana
Susana Chamorro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Priority to ES200100105A priority Critical patent/ES2187334B1/es
Priority to PCT/FR2002/000150 priority patent/WO2002057220A1/fr
Priority to ARP020100152A priority patent/AR032247A1/es
Publication of ES2187334A1 publication Critical patent/ES2187334A1/es
Application granted granted Critical
Publication of ES2187334B1 publication Critical patent/ES2187334B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

Nuevos derivados de la hidrazida, su procedimiento de preparación y las composiciones farmacéuticas que los contienen Compuestos de fórmula (I): R-NH-A-CO-NH-NH-(W){sub,n }-Z en la cual: - n equivale a 0 ó a 1, - W representa un grupo -CO- o un grupo S(O){sub,r} en el cual r equivale a 0, 1 ó 2, - Z representa un grupo seleccionado entre arilo, arilalquilo, heteroarilo heteroarilalquilo eventualmente sustituidos, y alquilo, - R representa un grupo seleccionado entre: Z{sub,1}-T-CO-,Z{sub,1}- O-T-CO-,Z{sub,1}-T-O-CO-,Z{sub,1}-T-S(O){sub,q}- en los cuales Z{sub,1}, T y q son tales como se han definido en la descripción, - A representa un grupo alquileno, alquenileno o alquinileno de 3 a 8 átomos de carbono, alquilencicloalquilenalquileno, alquilenarileno, arilenalquileno, alquilenarilenalquileno, un grupo **FIGURA-01** en el cual B{sub,1} es tal como se ha definido en la descripción, o bien A forma con el átomo de nitrógeno adyacente un grupo **FIGURA- 02** tal como se ha definido en la descripción. Medicamentos.
ES200100105A 2001-01-17 2001-01-17 Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. Expired - Lifetime ES2187334B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES200100105A ES2187334B1 (es) 2001-01-17 2001-01-17 Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PCT/FR2002/000150 WO2002057220A1 (fr) 2001-01-17 2002-01-16 Derives de l'hydrazide et les compositions pharmaceutiques qui les contiennent
ARP020100152A AR032247A1 (es) 2001-01-17 2002-01-17 Nuevos compuestos de hidrazida,un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200100105A ES2187334B1 (es) 2001-01-17 2001-01-17 Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Publications (2)

Publication Number Publication Date
ES2187334A1 ES2187334A1 (es) 2003-06-01
ES2187334B1 true ES2187334B1 (es) 2004-09-16

Family

ID=8496424

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200100105A Expired - Lifetime ES2187334B1 (es) 2001-01-17 2001-01-17 Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Country Status (3)

Country Link
AR (1) AR032247A1 (es)
ES (1) ES2187334B1 (es)
WO (1) WO2002057220A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008026563A1 (en) * 2006-08-30 2008-03-06 Shionogi & Co., Ltd. Hydrazine amide derivative
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027843A1 (en) * 1998-11-09 2000-05-18 Smithkline Beecham Corporation Ccr-3 receptor antagonists
ES2161594B1 (es) * 1998-12-17 2003-04-01 Servier Lab Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DUHAULT, J. et al.: Food intake regulation in rodents: Y5 or Y1 receptors or both?. Canadian J. of Physiol. Pharmacol., 2000, Vol. 78, nº 1, páginas 173-185. Página 177; figura 2; compuestos de la serie MON04. *
MILNE, H.B. et al.: Peptide Synthesis via oxidation of N-acyl-alpha-amino acid Phenylhydrazides. II. Benzyloxycarbonyl peptide Phenylhydrazides. J. Org. Chem., 1968, Vol. 33, nº 1, páginas 169-175. Tabla I. *

Also Published As

Publication number Publication date
WO2002057220A1 (fr) 2002-07-25
ES2187334A1 (es) 2003-06-01
AR032247A1 (es) 2003-10-29

Similar Documents

Publication Publication Date Title
ES2161594B1 (es) Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
NO20065178L (no) Tienopyridinderivater
ATE246196T1 (de) Sulphostinanaloga und verfahren zur herstellung von sulphostin und analoga davon
UY28121A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5-sustituidos
NO20053890L (no) Syntese av 4-amino-2-butenolklorider og anvendelse derav for fremstilling av 3-cyanokinoliner
ATE490788T1 (de) Antivirale phosphonate analoge
DE59814355D1 (de) Herstellung von organischen elektrolumineszierenden Bauteilen
AR035056A1 (es) Compuestos de poliarilcarboxamida, procesos para su preparacion , intermediarios utiles para la preparacion de tales compuestos, composiciones farmaceuticas que comprenden tales compuestos, y, el uso de tales compuestos en la fabricacion de medicamentos
NO20055383D0 (no) Fremgangsmate for fremstilling av 1,3-propandiol
CY1110738T1 (el) Παραγωγα aminoαλκυλβενζοϋλ-βενζοφουραν ή βενζοθειοφαιν, μεθοδος παρασκευης τους και συνθεσεις που τα περιεχουν
EA200300428A1 (ru) Антагонисты метаботропных рецепторов глутамата
DE69112989D1 (de) Aminocoumaranderivate, ihre Herstellung und Verwendung.
ATE372767T1 (de) Dpp-iv-hemmer
NO20043586L (no) Fremgangsmate for fremstilling av organiske forbindelser
MY145819A (en) Process and intermediates useful in the preparation of pharmaceutical compounds as fulvestrant
DE60304223D1 (de) Herstellung von metallamid-komplexen
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
AR040968A1 (es) Bifenilcarboxamidas sustituidas con n- aril piperidina, un metodo para su preparacion, composicion farmaceutica y proceso de preparacion
CO5550494A2 (es) Derivados de diamina, proceso para producir los derivados de diamina, y fungicidas que contienen los derivados de diamina como ingrediente activo
EP1241158A4 (en) CONNECTION WITH HYDROXYCARBONYL HALOGENALKYL SIDE CHAIN
DE602004023786D1 (de) Herstellung von hochreinem Alkylgallium
ATE349456T1 (de) Herstellung von 2-18f-2-desoxy-d-glucose durch festphasensynthese
ES2187334B1 (es) Nuevos derivados de la hidrazida, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
EA200000948A1 (ru) Новые полициклические азаиндолы, способ их получения и фармацевтические композиции, содержащие их
SE0400708D0 (sv) New compounds and use thereof

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030601

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2187334B1

Country of ref document: ES

FA2A Application withdrawn

Effective date: 20050301